GANYMED lead antibodies show excellent efficacy and safety in mouse tumor models
The GC182 target is a cell surface protein that is involved in cell-cell interactions. It was shown to be expressed with high prevalence and unique specificity in several solid cancers with high medical need (approx. 80% stomach cancers, 30% esophagus cancers, 25% lung and pancreatic cancers). The GC182 cell surface epitope that is targeted by GANYMED's antibodies is identical in mouse and man, and highly similar in other mammalian species. Thus, mouse xenograft models with GANYMED's GC182 antibodies can be considered as highly predictive pre-clinical models.
"This excellent animal data fully confirms our earlier analysis based on human immunohistochemistry and cell culture data." said Dr. Özlem Türeci, CSO and co-founder of GANYMED. "The experiments clearly demonstrate that our antibodies are highly effective against tumors that express GC182, without any apparent toxicity."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous